Komezol

Omeprazole, the active ingredient in Komezol, is a proton pump inhibitor presented as an oral tablet for oral use. It treats gastro‑esophageal reflux disease, peptic ulcer disease, erosive esophagitis and is used in combination regimens for Helicobacter pylori eradication in adult patients.

GNH USA supplies Komezol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent batch release, regulatory support, and competitive pricing across markets.

Omeprazole is indicated for conditions involving excess gastric acid production.

- Gastro‑esophageal reflux disease (GERD): reduces acid reflux symptoms and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing by decreasing gastric acid secretion. - Erosive esophagitis: aids mucosal repair and symptom relief in acid‑induced esophageal damage. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by creating a less acidic gastric environment.

Omeprazole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, usually transient. - Nausea: occasional stomach discomfort. - Abdominal pain: cramping or discomfort in the abdomen.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Osteoporotic fractures: increased risk of hip, wrist or spine fractures with long‑term use. - Acute interstitial nephritis: sudden kidney inflammation causing reduced urine output.

When prescribing Omeprazole, consider the following precautions to ensure safe use.

- Pregnancy: Category B; use only if potential benefit justifies the potential risk to the fetus. - Breastfeeding: Small amounts excreted in milk; monitor infant for possible effects. - Long‑term therapy: Assess need periodically to avoid risks such as nutrient malabsorption and bone density loss. - Renal impairment: Dose adjustment may be required; monitor renal function. - Hepatic impairment: Use with caution in patients with severe liver disease. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Omeprazole can affect the pharmacokinetics of several medicines; interactions may be major or moderate.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir (and other protease inhibitors): decreased absorption leading to loss of antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: Omeprazole may increase INR, requiring closer coagulation monitoring. - Digoxin: possible increase in serum levels; monitor for toxicity. - Methotrexate: reduced renal clearance may raise toxicity risk.